Simulations Plus Inc (OQ:SLP)

Business Focus: Medical Software & Technology Services

Apr 04, 2024 08:30 am ET
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that the U.S. FDA has renewed its
Apr 03, 2024 04:34 pm ET
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024.
Mar 20, 2024 04:06 pm ET
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024.
Mar 13, 2024 08:30 am ET
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn O’Connor, chief executive officer, will be hosting a fireside chat at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 4:30 p.m. Eastern Time. In addition, Mr. O’Connor will be meeting one-on-one with investors throughout the day.
Mar 05, 2024 08:30 am ET
Simulations Plus and the University of Bath Awarded New FDA Grant
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that, through a joint
Feb 15, 2024 08:30 am ET
Simulations Plus Extends Collaboration with Major Toxicology Research Agency
“At NIEHS, we seek to expand scientific knowledge and approach methods linking the environment and human health. The Division of Translational Toxicology (DTT) at NIEHS provides health effects research to federal, state and local health agencies to identify emerging public health issues and support the conduct of formal risk assessments and decision-making,” said Stephen Ferguson, Ph.D., scientific lead for the NIEHS project. “The agreement with Simulations Plus provides computational tools that support investigations of environmental chemicals and their potential health effects.”
Feb 13, 2024 09:15 am ET
Simulations Plus Launches Corporate Development Initiative
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today provided additional information on advancing its corporate allocation strategy, specifically increased focus on strategic investments and partnerships.
Feb 06, 2024 08:30 am ET
Simulations Plus to Participate in Upcoming Healthcare Conferences
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February.
Jan 30, 2024 08:30 am ET
Simulations Plus Releases GastroPlus® Version 9.9
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the release of
Jan 09, 2024 08:30 am ET
Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that, through a joi
Jan 03, 2024 04:06 pm ET
Simulations Plus Reports First Quarter Fiscal 2024 Financial Results
Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its first quarter fiscal 2024, ended November 30, 2023.
Jan 03, 2024 04:05 pm ET
Simulations Plus Announces Leadership Appointments Supporting Commitment to Clients and Driving Growth
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the following leadership changes effective January 3, 2024.
Dec 20, 2023 08:30 am ET
Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024.
Nov 14, 2023 08:00 am ET
Simulations Plus Outlines Paths to Win at 2023 Investor Day
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today will host its investor day virtually, as previously announced.
Nov 08, 2023 08:30 am ET
ISoP New Board of Trustees Members Announced
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced today that
Oct 31, 2023 08:30 am ET
Simulations Plus to Host Investor Day on Tuesday, November 14th
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it will hold a virtual Investor Day on Tuesday, November 14, 2023, beginning at 1:00 p.m. Eastern time. Presentations will be given by CEO Shawn O’Connor and members of the Simulations Plus leadership team who will share how putting customers first drives growth and fuels innovation.
Oct 25, 2023 04:06 pm ET
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its fourth quarter and fiscal 2023, ended August 31, 2023.
Oct 11, 2023 04:06 pm ET
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2023 financial results after the market close on Wednesday, October 25, 2023.
Sep 21, 2023 08:30 am ET
Simulations Plus Receives New FDA Grant Award
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced it has been awarded a new funded grant from the
Sep 07, 2023 08:30 am ET
Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced the successful completion of the inaugural University+ PBPK Summer Camp, an i
Aug 24, 2023 08:30 am ET
Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, is proud to announce that
Aug 15, 2023 08:30 am ET
Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today shared an article published in the July 2023 issue of Clinical Pharmacol
Jul 13, 2023 08:30 am ET
Simulations Plus Releases ADMET Predictor® 11
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the release of
Jul 06, 2023 04:06 pm ET
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its third quarter of fiscal 2023, ended May 31, 2023.
Jun 21, 2023 04:06 pm ET
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2023 financial results after the market close on Thursday, July 6, 2023.
Jun 20, 2023 08:00 am ET
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Immunetrics, Inc. (“Immunetrics”), a modeling and simulation company focused on accelerating drug development in oncology, immunology, and autoimmune diseases, areas that are among the fastest growing therapeutics.
May 10, 2023 08:30 am ET
Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of a new integrated pulmonary software and services package. This targe
Apr 18, 2023 08:30 am ET
Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that the U.S. FDA has renewed its licenses to the
Apr 05, 2023 04:06 pm ET
Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter of fiscal 2023, ended February 28, 2023.
Mar 30, 2023 08:30 am ET
MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science
More than 150 people from around the world gathered virtually this past February for a panel discussion about how to move the needle on gender equity for women in science.
Mar 28, 2023 08:30 am ET
Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it established a strategic research collaboration with the Sino-American Canc
Mar 21, 2023 04:06 pm ET
Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the second quarter of fiscal year 2023, the period ended February 28, 2023, after the close of the financial markets on Wednesday, April 5, 2023.
Mar 20, 2023 02:00 pm ET
Sidoti's Small-Cap Virtual March Conference
NEW YORK, NY / ACCESSWIRE / March 20, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 22-23, 2023. The links can also be found at www.sidoticonference.com/events.
Mar 16, 2023 08:30 am ET
Simulations Plus to Present at Sidoti March Small-Cap Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at the Sidoti Small-Cap Investor Conference taking place virtually on March 22-23, 2023.
Mar 15, 2023 08:30 am ET
Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it entered into a collaborative research agreement with the Institute of Medical
Mar 09, 2023 08:30 am ET
Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite™ in Version 2023R1
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its
Mar 07, 2023 08:30 am ET
Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at Oppenheimer’s 33rd Annual Healthcare Conference taking place virtually from March 13-15, 2023.
Feb 28, 2023 08:30 am ET
Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at the Raymond James & Associates’ 44th Annual Institutional Investors Conference, scheduled for March 5-8, 2023, at the JW Marriott Grande Lakes in Orlando, Florida.
Feb 16, 2023 08:30 am ET
Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered a new collaboration with a large agrochemicals company to ex
Feb 09, 2023 08:30 am ET
Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of NAFLDsym v2B Beta, a quantitative systems pharmacology (QSP) modeling
Jan 12, 2023 08:30 am ET
Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its
Jan 11, 2023 06:14 pm ET
Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered into an accelerated share repurchase agreement (the “ASR Agreement”) with Morgan Stanley & Co. LLC. to repurchase an aggregate of $20 million of the Company’s outstanding common shares. The ASR Agreement is part of the $50 million share repurchase program authorized by the Board of Directors on December 29, 2022. After completion of the repurchases under the ASR Agreement, $30 million will remain available for additiona
Jan 04, 2023 04:06 pm ET
Simulations Plus Reports First Quarter Fiscal 2023 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its first quarter of fiscal 2023, ended November 30, 2022.
Dec 19, 2022 04:06 pm ET
Simulations Plus Sets Date for First Quarter Fiscal Year 2023 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP) announced today that it will report financial results for the first quarter of fiscal year 2023, the period ended November 30, 2022, after the close of the financial markets on Wednesday, January 4, 2023.
Nov 15, 2022 08:30 am ET
Simulations Plus and the University of Bath Awarded New FDA Grant
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that, through a joint proposal with the University of Bath’s Department of Life Sciences
Nov 10, 2022 08:30 am ET
Gustavo Mendes Lima Santos Joins the Simulations Plus Regulatory Fellowship Program
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that
Nov 03, 2022 08:30 am ET
Simulations Plus 25th Anniversary Celebration Concludes with $25,000 Gift to Nonprofit, Girls Who Code
Simulations Plus (Nasdaq: SLP) today announced its final donation in celebration of 25 years in business. During this 25th anniversary year, which commenced in July 2021, teams of long-tenured Simulations Plus employees researched various organiza
Nov 02, 2022 08:30 am ET
Simulations Plus and the University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled Products
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that, through a joint proposal with the University of Florida’s College of Pharma
Oct 26, 2022 04:06 pm ET
Simulations Plus Reports Fourth Quarter and Full Fiscal Year 2022 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its fourth quarter and full-year fiscal 2022, ended August 31, 2022.
Oct 20, 2022 04:15 pm ET
Simulations Plus Announces Cash Dividend
Simulations Plus, Inc. (Nasdaq: SLP) announced today that the Company’s Board of Directors has declared a cash dividend of $0.06 per share of the Company’s common stock, payable on November 7, 2022, to shareholders of record as of October 31, 2022. The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.
Oct 12, 2022 08:30 am ET
Simulations Plus Releases GastroPlus® Version 9.8.3
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of version 9.8.3 of its flagship physiologically based biopharmaceutics (PBBM) / pharmac
Oct 11, 2022 04:06 pm ET
Simulations Plus Sets Date for Fourth Quarter and Fiscal Year 2022 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2022, the period ended August 31, 2022, after the close of the financial markets on Wednesday, October 26, 2022.
Sep 20, 2022 02:45 pm ET
Sidoti's September Small-Cap Virtual Conference
NEW YORK, NY / ACCESSWIRE / September 20, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day September Small-Cap Conference taking place Wednesday and Thursday, September 21-22, 2022. The links can also be found at www.sidoticonference.com/events .
Sep 14, 2022 08:30 am ET
Simulations Plus to Present at Sidoti Fall Small Cap Investor Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at the Sidoti Fall Small Cap Investor Conference taking place virtually on September 21-22, 2022.
Sep 07, 2022 08:30 am ET
Simulations Plus to Present at Baird 2022 Global Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at Baird’s 2022 Global Healthcare Conference taking place September 13-14, 2022, at the InterContinental New York Barclay Hotel.
Aug 31, 2022 08:30 am ET
Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its
Aug 04, 2022 08:30 am ET
Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pKa)
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered a new collaboration with a large pharmaceutical
Jul 26, 2022 08:30 am ET
Simulations Plus Presented New Scientific Developments at PAGE 2022
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the presentation of five scientific posters by Simulations Plus scientists at the Pop
Jul 21, 2022 08:30 am ET
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childhood Cancer
Simulations Plus (Nasdaq: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to
Jul 14, 2022 08:30 am ET
Simulations Plus Realizes Early Success with its Concierge Program
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, recently invested in the creation of their
Jul 06, 2022 04:06 pm ET
Simulations Plus Reports Third Quarter Fiscal 2022 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its third quarter of fiscal 2022, ended May 31, 2022.
Jun 30, 2022 08:30 am ET
Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced record-setting attendance and virtual content delivery for the 2022 Pharmacometrics Spring School using MonolixSuite™. New for 2022 was the introduction of the “NCA, bioequivalence, and beyond! Spring School” course using PKanalix™. Both workshops were held in March 2022.
Jun 23, 2022 08:30 am ET
Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy. This modeling and simulation work provided significant contributions towards regulatory submissions for the compound.
Jun 21, 2022 04:06 pm ET
Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the third quarter of fiscal year 2022, the period ended May 31, 2022, after the close of the financial markets on Wednesday, July 6, 2022.
Jun 16, 2022 08:30 am ET
DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has published important simulation results performed with the quantitative systems toxicology model,
May 26, 2022 08:30 am ET
Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the release of version 10.4 (X.4) of its flagship machine learning modeling platform,
May 05, 2022 08:30 am ET
U.S. FDA Renews Annual DILIsym Software Licenses for 2022
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that the U.S. Food and Drug Administration (FDA) has renewed its licenses to the DILIsym® software platform, the DILIsym Services division’s flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI). The one-year renewal provides continued DILIsym software access to FDA employees across all FDA divisions at their discretion through an unlimited licensing packag
Apr 28, 2022 08:30 am ET
Simulations Plus Successfully Delivers FDA-Funded Project
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the completion of a newly funded project from the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG), through a collaboration of its Lixoft and Cognigen divisions, to establish the suitability of model-integrated evidence to demonstrate bioequivalence (BE) for long-acting injectable (LAI) and implantable drug products.
Apr 21, 2022 08:30 am ET
Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new funded collaboration with a large pharmaceutical company to expand and validate the mechanistic in vitro dissolution models for intravitreal injectable formulations within the
Apr 19, 2022 08:30 am ET
Simulations Plus to Present at the Berenberg Discover AI Seminar
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be participating in the Berenberg Discover AI Seminar at The Newbury Boston in Boston, Massachusetts, on April 26, 2022.
Apr 06, 2022 04:06 pm ET
Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter of fiscal 2022, ended February 28, 2022.
Mar 29, 2022 08:30 am ET
Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software
Dr. Paul Watkins, the Director of the Institute for Drug Safety Sciences at University of North Carolina and consultant for the project, said: “The liver QST software provided by Simulations Plus,
Mar 24, 2022 08:30 am ET
Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and
Mar 22, 2022 04:10 pm ET
Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the second quarter of fiscal year 2022, the period ended February 28, 2022, after the close of the financial markets on Wednesday, April 6, 2022.
Mar 17, 2022 08:30 am ET
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare Disorders
Simulations Plus (Nasdaq: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to the National Organization for Rare Disorders (“NORD”), headquartered in Quincy, MA.
Mar 10, 2022 08:30 am ET
Simulations Plus Releases MembranePlus 3.0
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced it has released
Mar 08, 2022 08:30 am ET
Simulations Plus to Present at Oppenheimer Annual Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at Oppenheimer’s 32nd Annual Healthcare Conference taking place virtually from March 15-16, 2022.
Mar 02, 2022 08:30 am ET
Simulations Plus to Present at Raymond James Institutional Investors Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at the Raymond James & Associates’ 43rd Annual Institutional Investors Conference, scheduled for March 6-9, 2022, at the JW Marriott Grande Lakes in Orlando, Florida.
Feb 08, 2022 08:30 am ET
Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be participating in BTIG’s MedTech, Digital Health, Life Science and Diagnostic Tools Conference, taking place virtually from February 15-17, 2022.
Jan 20, 2022 08:30 am ET
Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new funded collaboration with a large pharmaceutical
Jan 18, 2022 07:30 am ET
Sidoti Winter Virtual Small Cap Investor Conference
NEW YORK, NY / ACCESSWIRE / January 18, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Small Cap Virtual Conference taking place Wednesday and Thursday, December 19th-20th, 2022. The links can also be found at www.sidoticonference.com/events.
Jan 13, 2022 08:30 am ET
Simulations Plus Enters New Collaboration with Leading Animal Health Company
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new funded collaboration with a large animal hea
Jan 12, 2022 08:30 am ET
Simulations Plus to Present at Sidoti Winter Small Cap Investor Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at the Sidoti Winter Small Cap Investor Conference taking place virtually on January 19–20, 2022.
Jan 06, 2022 04:06 pm ET
Simulations Plus Reports First Quarter Fiscal 2022 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its first quarter of fiscal 2022, ended November 30, 2021.
Jan 05, 2022 08:30 am ET
Lixoft Adds New Bioequivalence Module in MonolixSuite® Version 2021R1
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Lixoft division, a leading provider of population PKPD modeling solutions for pharmacometricians and biostatisticians, has released an update to version 2021R1 of its
Dec 20, 2021 04:10 pm ET
Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the first quarter of fiscal year 2022, the period ended November 30, 2021, after the close of the financial markets on Thursday, January 6, 2022.
Dec 02, 2021 08:30 am ET
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has extended its distributor agreement in Japan with Northern Science Consulting for Monolix.
Nov 30, 2021 09:00 am ET
Simulations Plus celebrates 25-year anniversary with $25,000 gift to nonprofit Dispensary of Hope
NASHVILLE, Tenn., Nov. 30, 2021 /PRNewswire/ -- Simulations Plus (NASDAQ: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to the Dispensary of Hope. Dispensary of Hope is a national nonprofit medication distributor headquartered in Nashville, TN.
Nov 30, 2021 08:30 am ET
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope
Simulations Plus, Inc. (Nasdaq: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to the Dispensary of Hope. Dispensary of Hope is a national nonprofit medication distributor headquartered in Nashville, Tenn.
Nov 19, 2021 08:30 am ET
Simulations Plus Names Sharlene Evans to Board of Directors
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has named Sharlene Evans, a proven executive with over 25 years of experience in operations, human resources, and personnel development, to the Company’s Board of Directors. Ms. Evans will replace David L. Ralph, Ph.D. on the Simulations Plus Board of Directors. Dr. Ralph is retiring from the Board after nine years of service. Ms. Evans will serve on the Audit and Compensation committees and will st
Nov 18, 2021 08:30 am ET
Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it presented simulation results performed with the quantitative systems pharmacology model, NAFLDsym, to help explain the relatively high positive response rates in placebo cohorts. Numerous recent late-stage clinical trials for potential treatments of non-alcoholic steatohepatitis (NASH) have included relatively high positive response rates in the placebo cohorts, despite not being provided the actual treatments. The high rates
Nov 16, 2021 08:30 am ET
Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury
Dr. Brett Howell, president of the DILIsym Services division, remarked: “DILIsym continues to be used for
Oct 28, 2021 08:30 am ET
Simulations Plus Releases GastroPlus® Version 9.8.2
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced the release of version 9.8.2 of its flagship physiologica
Oct 26, 2021 08:30 am ET
Simulations Plus and the University of Connecticut Awarded New FDA Contract to Accelerate the Development of Long-Acting Injectable Products
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced that, through a joint proposal with the University of Connecticut’s Department of Pharm
Oct 25, 2021 04:06 pm ET
Simulations Plus Reports Fourth Quarter and Full Year Fiscal 2021 Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today reported financial results for its fourth quarter and full year 2021 fiscal year, ended August 31, 2021.
Oct 21, 2021 08:30 am ET
Simulations Plus Announces the University+ Program
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the formation of the
Oct 13, 2021 08:30 am ET
Simulations Plus Announces Cash Dividend
Simulations Plus, Inc. (Nasdaq: SLP) announced today that the Company’s Board of Directors has declared a cash dividend of $0.06 per share of the Company’s common stock, payable on November 1, 2021, to shareholders of record as of October 25, 2021. The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.
Oct 11, 2021 04:15 pm ET
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2021 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2021, ended August 31, 2021, after the close of the financial markets on Monday, October 25, 2021.
Sep 23, 2021 08:30 am ET
Simulations Plus Receives New Grant Award From the FDA
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has received notice from the
Sep 15, 2021 08:30 am ET
Simulations Plus Releases ADMET Predictor® (X.3)
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has released version 10.3 of its flagship machine le
Sep 08, 2021 08:30 am ET
Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at two upcoming investor conferences:
Aug 19, 2021 08:30 am ET
Simulations Plus Reports Continued Success in Second Phase of AIDD Collaboration with Large Pharmaceutical Company
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has received the second phase of experimental results from a collaborative research agreement it entered with a large pharmaceutical company in mid-2020 to evaluate the impact of the new
Aug 04, 2021 08:30 am ET
NMPA’s Center for Drug Evaluation Adds Licenses of GastroPlus®
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has received an order from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China to add licenses to GastroPlus®.
Jul 12, 2021 04:05 pm ET
Simulations Plus Reports Third Quarter Fiscal 2021 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today reported financial results for its third quarter of fiscal 2021, ended May 31, 2021.
Jul 08, 2021 08:30 am ET
Simulations Plus Celebrates 25 Years in Business
This month marks the 25th anniversary of Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries. In celebration of its achievements, Simulations Plus will host a series of exciting events throughout the year to share the milestones and challenges of the last 25 years while looking ahead to future opportunities.
Jun 28, 2021 04:15 pm ET
Simulations Plus Sets Date for Third Quarter Fiscal Year 2021 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its financial results for the third quarter of fiscal year 2021, the period ended May 31, 2021, after the close of the financial markets on Monday, July 12, 2021.
Jun 17, 2021 08:30 am ET
Simulations Plus Releases IPFsym version 1A, State-of-the-Art Quantitative Systems Pharmacology (QSP) Software for Idiopathic Pulmonary Fibrosis (IPF)
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has released
May 27, 2021 08:30 am ET
Simulations Plus to Participate in 18th Annual Craig-Hallum Institutional Investor Conference
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will participate in Craig-Hallum’s 18th Annual Institutional Investor Conference on Wednesday, June 2, 2021.
May 13, 2021 08:30 am ET
Simulations Plus to Present at 16th Annual Needham Virtual Technology & Media Conference
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 16th Annual Needham Virtual Technology and Media Conference on Thursday, May 20, 2021, at 1:30 p.m. ET. In addition to his presentation, Mr. O’Connor will be joined by chief financial officer Will Frederick to host one-on-one meetings throughout the day.
May 12, 2021 08:30 am ET
Simulations Plus Uplisted to The Nasdaq Global Select Market®
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that its shares of common stock have been approved for trading on The Nasdaq Global Select Market® effective as of the market open on Thursday, May 13, 2021, and will continue trading under its current ticker symbol SLP.
Apr 27, 2021 08:30 am ET
Simulations Plus Releases ADMET Predictor® (X.2)
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has released version 10.2 of its flagship machine learning modeling platform,
Apr 20, 2021 08:30 am ET
U.S. FDA Renews Licenses of DILIsym Software
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has renewed licen
Apr 12, 2021 04:05 pm ET
Simulations Plus Reports Record Second Quarter Fiscal 2021 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today reported financial results for its second quarter of fiscal 2021, ending February 28, 2021.
Apr 07, 2021 08:30 am ET
Simulations Plus Reports Successful Results from AIDD Collaboration with Large Pharmaceutical Company
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has received initial experimental results from a collaborative research agreement it entered with a large pharmaceutical company in mid-2020 to evaluate the impact of the generative chemistry technology contained in the new
Mar 29, 2021 04:05 pm ET
Simulations Plus Sets Date for Second Quarter Fiscal Year 2021 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its financial results for the second quarter of fiscal year 2021, the period ended February 28, 2021, after the close of the financial markets on Monday, April 12, 2021.
Mar 16, 2021 08:30 am ET
Simulations Plus Forms Scientific Advisory Board for RENAsym Consortium
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has formed a Scientific Advisory Board (SAB) to provide guidance and direction for development of its RENAsym quantitative systems toxicology (QST) kidney injury software platform.
Mar 11, 2021 08:30 am ET
Simulations Plus Hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and
Mar 09, 2021 08:30 am ET
Simulations Plus to Present at Oppenheimer Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, will be presenting at Oppenheimer’s 31st Annual Healthcare Conference on Tuesday, March 16, 2021. Mr. O’Connor’s presentation, which will be webcast live, will begin at 2:30 p.m. ET. In addition, Mr. O’Connor and chief financial officer Will Frederick will host one-on-one meetings throughout the day.
Feb 23, 2021 08:30 am ET
Simulations Plus and the University of Pittsburgh Drug Discovery Institute Receive SBIR Grant Funding for Large Molecule Safety Collaboration
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and
Feb 11, 2021 08:30 am ET
Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, and Will Frederick, chief financial officer, will be hosting a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021, beginning at 12:00 p.m. EST. The Company will also host one-on-one meetings throughout the day.
Feb 09, 2021 08:30 am ET
Simulations Plus Releases GastroPlus® Version 9.8.1
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has released version 9.8.1 of its flagship physio
Feb 02, 2021 08:30 am ET
Simulations Plus Enters Agreement with Distributor in China
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a distribution agreement with M
Jan 26, 2021 08:30 am ET
Simulations Plus Expands Marketing and Sales Operations in South America Through Partnership with the Institute of Pharmaceutical Sciences
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a distribution agreement with t
Jan 14, 2021 08:30 am ET
Simulations Plus Awards Infrastructure Improvement Grant to Makerere University Department of Pharmacology and Therapeutics
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of population pharmacokinetic and pharmacodynamic modeling and simulation services, today announced that its Cognigen divisi
Jan 12, 2021 08:45 am ET
Simulations Plus to Present at 23rd Annual Needham Virtual Growth Conference
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 23rd Annual Needham Virtual Growth Conference on Thursday, January 14, 2021, at 2:00 p.m. ET. In addition to his presentation, Mr. O’Connor will host one-on-one meetings throughout the day.
Jan 12, 2021 08:30 am ET
Simulations Plus Enters New Funded Collaboration to Improve Lung Exposure Models for Pulmonary Infection Treatments
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to develop machine learning models and enhance physiologically based pharmacokinetics / pharmacodynamics (PBPK/PD) approaches for potential treatments of pulmonary infections.
Jan 11, 2021 04:05 pm ET
Simulations Plus Reports Record First Quarter FY2021 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its first quarter of fiscal year 2021.
Jan 05, 2021 08:30 am ET
Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides
“Our partner, a frequent user of the GastroPlus platform across multiple research sites worldwide, has a growing portion of their development pipeline focused on therapeutic peptides and proteins,” said
Jan 04, 2021 08:30 am ET
Simulations Plus Sets Date for First Quarter Fiscal Year 2021 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its financial results for the first quarter of fiscal year 2021, ended November 30, 2020, after the close of the financial markets on Monday, January 11, 2021.
Dec 16, 2020 08:30 am ET
Simulations Plus Publishes its Inaugural Environmental, Social and Governance (ESG) Report
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has published its inaugural Environmental, Social,
Dec 03, 2020 08:30 am ET
DILIsym Services Presents Important DILIsym and NAFLDsym Software Applications at the Virtual AASLD Liver Meeting
DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that important applicati
Dec 01, 2020 04:05 pm ET
Simulations Plus Names Industry Veteran Will Frederick as Chief Financial Officer
Simulations Plus, Inc. (Nasdaq: SLP), announced today the appointment of Will Frederick as chief financial officer (CFO), succeeding John Kneisel, who retires after seven years with the company.
Nov 16, 2020 04:05 pm ET
Simulations Plus Reports FY2020 and Fourth Quarter FY2020 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its 2020 fiscal year (FY20) and fourth quarter (4QFY20) ended August 31, 2020.
Nov 10, 2020 08:30 am ET
DILIsym Plays Critical Role in Submission to State of California for Common Analgesic Carcinogenicity Risk Assessment
DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of
Nov 09, 2020 08:30 am ET
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2020 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2020, ended August 31, 2020, after the close of the financial markets on Monday, November 16, 2020.
Nov 05, 2020 08:30 am ET
Simulations Plus to Participate in the Credit Suisse Virtual Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will be participating in the Credit Suisse 29th Annual Virtual Healthcare Conference on Tuesday, November 10, 2020. Mr. O’Connor’s presentation will begin at 3:30 p.m. ET and will be webcast live.
Nov 03, 2020 08:30 am ET
Lixoft Expands MonolixSuite™ in Version 2020R1
Lixoft, a Simulations Plus company (Nasdaq: SLP), a leading provider of population PKPD modeling solutions for pharmacometricians and biostatisticians, today announced that it has released version 2020R1 of its
Oct 27, 2020 08:30 am ET
First Approved Cancer Treatment for TGCT Included DILIsym Simulations in FDA Review
DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of
Oct 20, 2020 08:30 am ET
Simulations Plus Releases GastroPlus® Version 9.8
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.8 of the preeminent platfo
Oct 13, 2020 08:30 am ET
Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that its board of directors has declared another quarterly cash dividend of $0.06 per share of the Company’s common stock. The cash dividend will be distributed on Monday, November 2, 2020, to shareholders of record as of Monday, October 26, 2020.
Oct 13, 2020 08:30 am ET
Simulations Plus Teams Up with the University of Health Sciences and Pharmacy in St. Louis to Secure New Grant Award from the U.S. FDA
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that, through a joint proposal with the St. Louis Co
Sep 29, 2020 08:30 am ET
Simulations Plus Extends Partnership with Large Pharmaceutical Company to Further Expand High-Throughput PBPK Capabilities in ADMET Predictor®
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into an accelerated second phase of its collaboration with a large pharmaceutical company to tailor its high-throughput pharmacokinetic (HTPK) simulation functionality within
Sep 22, 2020 08:30 am ET
Simulations Plus Partners with Large Pharmaceutical Company to Validate AI-Driven Drug Design Capabilities in ADMET Predictor®
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it entered into a collaborative research agreement w
Sep 15, 2020 08:30 am ET
Sep 02, 2020 08:30 am ET
FDA Review of Approved Drug, Ubrogepant, Included DILIsym Simulations
DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that simulations using the DILIsym®
Aug 31, 2020 05:00 pm ET
LD Micro - 360 Companies Set to Present - this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 31, 2020 08:30 am ET
Simulations Plus to Present at the LD 500 Virtual Conference
Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will be presenting at the LD 500 Virtual Conference on Wednesday, September 2, 2020, at 1:
Aug 10, 2020 04:01 pm ET
Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical, biotechnology, agrochemical, cosmetics and food industries, today announced the closing of its previously announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55.00 per share, which included the full exercise of the underwriters’ option to purchase 272,727 additional shares of common stock. The aggregate gross proceeds to Simulations Plus from this offering were approxi
Aug 05, 2020 10:28 pm ET
Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical, biotechnology, agrochemical, cosmetics and food industries, today announced the entry into an underwriting agreement relating to the sale of 1,818,182 shares of its common stock at an offering price of $55.00 per share, less underwriting discounts and commission. The offering is expected to close on or about August 10, 2020, subject to satisfaction of customary closing conditions. Simulations Plus has granted the
Aug 04, 2020 07:00 am ET
Simulations Plus Announces Proposed Underwritten Public Offering
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical, biotechnology, agrochemical, cosmetics and food industries, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.
Jul 09, 2020 04:05 pm ET
Simulations Plus Reports Third Quarter FY2020 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its third quarter of fiscal year 2020 (3QFY20) and the first nine months of fiscal year 2020 (9moFY20), the period ended May 31, 2020.
Jul 02, 2020 08:30 am ET
Simulations Plus Sets Date for 3rd Quarter 2020 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the third quarter of its 2020 fiscal year, the period ended May 31, 2020, on Thursday, July 9, 2020.
May 28, 2020 08:30 am ET
Simulations Plus Receives New Grant Award from the FDA
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received
May 27, 2020 05:48 pm ET
Hudson Pacific Properties Set to Join S&P MidCap 400; Diversified Healthcare Trust, Palomar Holdings & Simulations Plus to Join S&P SmallCap 600
NEW YORK, May 27, 2020 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Monday, June 1:
May 21, 2020 08:30 am ET
Simulations Plus to Present at 17th Annual Craig-Hallum Institutional Investor Conference
Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will participate in Craig-Hallum’s 17th Annual Institutional Investor Conference on Wednesday, May 27, 2020, beginning at 10:00 a.m. ET.
May 13, 2020 08:30 am ET
Simulations Plus to Present at 15th Annual Needham Virtual Technology & Media Conference
Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 15th Annual Needham Virtual Technology & Media Conference on Wednesday, May 20, at 10:00 a.m. ET. In addition to his presentation, Mr. O’Connor will host one-on-one meetings throughout the day.
May 06, 2020 08:30 am ET
U.S. FDA Renews Annual DILIsym Software Licenses
DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that the U.S. Food and Drug Adminis
Apr 09, 2020 04:35 pm ET
Simulations Plus Reports Record Second Quarter FY2020 Revenue
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its second quarter of fiscal year 2020, the period ended February 29, 2020 (2QFY20).
Apr 07, 2020 08:30 am ET
 Simulations Plus Partners with Large Pharmaceutical Company to Enhance High-Throughput PBPK Capabilities in ADMET Predictor®
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new collaboration agreement with a large pharmaceutical company to advance its
Apr 02, 2020 04:15 pm ET
Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2020 fiscal year, the period ended February 29, 2020, on Thursday, April 9, 2020.
Apr 02, 2020 08:30 am ET
Simulations Plus Acquires Lixoft, Expanding Modeling Software Offerings and Broadening Presence in Europe
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has acquired Lixoft of Paris, France. Lixoft was founded in 2011 by Jérôme Kalifa and Marc Lavielle to design software soluti
Mar 26, 2020 01:46 pm ET
Simulations Plus Offers Rapid Response COVID-19 Research Initiative
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the establishment of the Stra
Mar 18, 2020 08:30 am ET
Sandra Suarez-Sharp Joins Simulations Plus to Lead Regulatory Strategies Team
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that
Feb 04, 2020 08:30 am ET
DILIsym Services Partners with Large Pharmaceutical Company to Begin QSP Model Development for Heart Failure
DILIsym Services Inc. (DSS), a Simulations Plus company (Nasdaq: SLP) and a leading provider of simulation and modeling software for pharmaceutical efficacy and safety, today announced that it is developing a new component for a QSP model focused on treating heart failure, such as can occur after myocardial infarction. As with other QSP efforts by the company, the development of this new QSP software component is being sponsored by a large pharmaceutical company partner and will be widely available via licensing and consulting for the broader pharmaceutical industry upon completion.
Jan 13, 2020 05:30 am ET
Simulations Plus to Present at the 22nd Annual Needham Growth Conference
Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 22nd Annual Needham Growth Conference in New York City on Wednesday, January 15, 2020, at 4:50 p.m. ET. In addition to his presentation, Mr. O’Connor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.
Jan 09, 2020 04:05 pm ET
Simulations Plus Reports Record First Quarter FY2020 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its first quarter of fiscal year 2020, the period ended November 30, 2019 (1QFY20).
Jan 03, 2020 08:30 am ET
Simulations Plus Sets Date for First Quarter Fiscal Year 2020 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its first quarter financial results for fiscal year 2020, the period ended November 30, 2019, after the close of the financial markets on Thursday, January 9, 2020.
Dec 05, 2019 08:30 am ET
Simulations Plus Partners with Bayer AG to Develop New Cheminformatics Capabilities in ADMET Predictor
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new collaboration agreement with Bayer AG to advance its ADMET Predictor
Nov 21, 2019 08:30 am ET
Simulations Plus Partners with Large Pharmaceutical Company to Add New Capabilities to PKPlus
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new f
Nov 14, 2019 08:30 am ET
Simulations Plus Partners with Large Pharmaceutical Company to Enhance the Mechanistic Oral Absorption (ACAT) Model in GastroPlus
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new funde
Nov 13, 2019 04:05 pm ET
Simulations Plus Reports FY2019 and Fourth Quarter FY2019 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its 2019 fiscal year (FY19) and fourth quarter (4Q19) ended August 31, 2019.
Nov 06, 2019 08:30 am ET
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2019 Earnings Release and Conference Call
The Company invites all interested persons to attend its conference call at 4:15 p.m. Eastern Time on November 13, 2019. The live webcast/teleconference will be accessible by registering here. Please dial in five to ten minutes prior to the scheduled start time. A live, listen-only webcast will also be available by dialing (914) 614-3221,
Oct 29, 2019 08:30 am ET
Simulations Plus to Support Development of Radiation Countermeasure via New QSP Platform (RADAsym) and Pharmacometrics Modeling
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it is supporting the drug development program for a lifesaving countermeasure to acute radiation syndrome (ARS) in a partnership with a global pharmaceutical company.
Oct 17, 2019 08:30 am ET
Simulations Plus Partners with Large Pharmaceutical Company to Develop the Virtual Bioequivalence Trial Simulator™ Module
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new f
Oct 14, 2019 02:30 pm ET
Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.06 per share of the Company’s common stock. The cash dividend will be distributed on Friday, November 1, 2019, to shareholders of record as of Friday, October 25, 2019.
Oct 02, 2019 08:30 am ET
Simulations Plus Announces Leadership Changes at Cognigen
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announc
Sep 04, 2019 08:30 am ET
Simulations Plus Partners with Clinical-Stage Biotech Company to Develop Novel Dosing Models
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new funded
Jul 16, 2019 08:30 am ET
Simulations Plus Enters into New Research Collaboration Agreement with the FDA
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new five-year Research Collaboration Agreement with the U.S. Food and Drug Administration’s (FDA) Center for Veterinary Medicine to evaluate alternative approaches for determining product bioequivalence (BE) for locally-acting drugs in animals.
Jul 10, 2019 04:05 pm ET
Simulations Plus Reports Third Quarter FY2019 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its third quarter of fiscal year 2019 (3QFY19) and the first nine months of fiscal year 2019 (9moFY19), the period ended May 31, 2019.
Jul 09, 2019 08:30 am ET
Simulations Plus Upgrades PKPlus™
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the launch of version 2.5 of PKPlus, an update to its software for
Jul 02, 2019 08:30 am ET
Simulations Plus Sets Date for 3rd Quarter 2019 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP) announced today that it will report its third quarter financial results for fiscal year 2019, the period ended May 31, 2019, after the close of the financial markets on Wednesday, July 10. 2019.
Jun 27, 2019 08:30 am ET
DILIsym Releases NAFLDsym® Version 2A
DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released NAFLDsym® Version 2A,
Jun 18, 2019 08:30 am ET
Simulations Plus Upgrades Flagship GastroPlus
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.7 of its flagship physiologically based pharmacokinetic (PBPK) modeling platform, 
Jun 11, 2019 08:30 am ET
Cognigen Launches KIWI Version 4.0
Cognigen Corporation, a Simulations Plus company (Nasdaq: SLP) and a leading provider of population pharmacokinetic and pharmacodynamic modeling and simulation services, toda
May 21, 2019 08:30 am ET
PMDA Adds Licenses of GastroPlus®
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to add licenses to its GastroPlus® software suite.
May 16, 2019 08:30 am ET
U.S. FDA Renews DILIsym Software Licenses
DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that the U.S. Food and Drug Administration has renewed its multi-seat license for the company’s flagship quantitative systems toxicology (QST) modeling software,
May 14, 2019 08:30 am ET
Simulations Plus to Present at B. Riley FBR Investor Conference on May 22, 2019
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22, at 10:30 a.m. (PDT) in Room 8
May 01, 2019 04:15 pm ET
Lisa LaVange, PhD, Appointed to Board of Directors of Simulations Plus
Simulations Plus, Inc. (Nasdaq:SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced the appointment of Dr. Lisa LaVange to the Company’s Board of Directors. With a distinguished career spanning more than 35 years, Dr. LaVange brings expertise in biostatistics and experience with academia, commercial organizations, including Quintiles, the largest pharmaceutical outsourcing services company in the U.S., and government regulators, i
Apr 30, 2019 08:30 am ET
FDA Purchases Bundle of ADMET Predictor® Licenses
Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the U.S. Food and Drug Administration (FDA) for a 15-user license to its ADMET Predictor® software suite. The purchase was made by the
Apr 11, 2019 08:30 am ET
Simulations Plus Releases ADMET Predictor® Version 9.5
Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.5 of its flagship machine learning modeling platform, ADMET Predictor®
Apr 11, 2019 07:50 am ET
Report: Developing Opportunities within Floor & Decor, Carvana, Phibro Animal Health, Simulations Plus, Nature's Sunshine Products, and Jernigan Capital — Future Expectations, Projections Moving into
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Floor & Decor Holdings, Inc. (NYSE:FND), Carvana Co. (NYSE:CVNA),...
Apr 09, 2019 04:05 pm ET
Simulations Plus Reports Record Second Quarter FY2019 Revenue
Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its second quarter of fiscal year 2019, the period ended February 28, 2019 (2QFY19).
Apr 02, 2019 08:30 am ET
Simulations Plus Sets Date for 2nd Quarter 2019 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2019 fiscal year, the period ended February 28, 2019, on Tuesday, April 9, 2019.
Jan 17, 2019 08:30 am ET
DILIsym Awarded $1.5 Million Phase II NIH Grant
DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it has been awarded $1.5 million from Phase II of its previously announced Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). The second phase of the grant funding will support DILIsym Services’
Jan 15, 2019 08:30 am ET
Simulations Plus Releases DDDPlus™ Version 6
Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 6 of its in vitro dissolution modeling software,
Jan 14, 2019 08:30 am ET
DILIsym Services Inc. Initiates Development of IPFsym™
DILIsym Services Inc., a Simulations Plus company (Nasdaq:SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it is initiating development of IPFsym™, QSP (quantitative systems pharmacology) modeling software that will provide th
Jan 10, 2019 08:30 am ET
Simulations Plus to Present at the 21st Annual Needham Growth Conference
Simulations Plus, Inc. (Nasdaq:SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 21st Annual Needham Growth Conference in New York City on Wednesday, January 16, 2019, at 8:40 a.m. ET (5:40 a.m. PT). In addition to his presentation, Mr. O’Connor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.
Jan 09, 2019 04:05 pm ET
Simulations Plus Reports First Quarter FY2019 Financial Results
Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its first quarter of fiscal year 2019, the period ended November 30, 2018 (1QFY19).
Jan 07, 2019 08:30 am ET
DILIsym Services Inc. Releases DILIsym® Version 8A
DILIsym Services Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released DILIsym® Version
Jan 02, 2019 08:30 am ET
Simulations Plus to Report First Quarter Fiscal Year 2019 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its first quarter financial results for fiscal year 2019, the period ended November 30, 2018, after the close of the financial markets on Wednesday, January 9, 2019.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.